Evaluation of the steroid treatment of asthma since 1950

Baldwin, Horace S.; Dworetzky, Murray; Isaacs, Norman J.

doi:10.1016/0021-8707(61)90063-6

Cited by 12 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Failure Rate.-The failure rate of 5 to 20% is in agreement with the literature, which records rates from about 10% (Andersson and Bruun, 1960;Phear et al, 1960;Baldwin et al, 1961) to about 30% (Arnoldsson, 1958;Pearson et al, 1961). Our low failure rate may be explained by our care to exclude patients with bronchitis from this series.…”

Section: Discussionsupporting

confidence: 87%

“…There are now many favourable reports on the value of long-term steroid therapy in chronic intractable asthma (Gay et al, 1954;Arnoldsson, 1958;Williams, 1959;Phear et al, 1960;Serafini, 1960;Andersson and Bruun, 1960;Herxheimer, 1961;Pearson et al, 1961;Livingstone and Davies, 1961;Baldwin et al, 1961). That there is still confusion of thought on this subject is shown by the recent communications of Grant (1961), Asher (1961), Maxwell (1961), and Hart and Emerson (1961).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Long-term Steroid Therapy in Chronic Intractable Asthma

Rees¹,

Williams²

1962

BMJ

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 87%

mentioning

confidence: 99%

Long-term Steroid Therapy in Chronic Intractable Asthma

Rees¹,

Williams²

1962

BMJ

View full text Add to dashboard Cite

“…Moreover, asthma can be categorized by endotypes related to the biomarkers involved in the disease mechanisms (Chung, 2018). The traditional asthma treatment is corticosteroid drugs, which have been used since the middle of the last century (Baldwin et al, 1961). For many patients, inhaled corticosteroids, in combination or not with long-acting β2 agonists, are an effective treatment, suppressing airway inflammation and constriction, although it is not curative.…”

Section: Introductionmentioning

confidence: 99%

Emerging Cell-Based Therapies in Chronic Lung Diseases: What About Asthma?

Cereta

Oliveira²,

Costa

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Asthma is a widespread disease characterized by chronic airway inflammation. It causes substantial disability, impaired quality of life, and avoidable deaths around the world. The main treatment for asthmatic patients is the administration of corticosteroids, which improves the quality of life; however, prolonged use of corticosteroids interferes with extracellular matrix elements. Therefore, cell-based therapies are emerging as a novel therapeutic contribution to tissue regeneration for lung diseases. This study aimed to summarize the advancements in cell therapy involving mesenchymal stromal cells, extracellular vesicles, and immune cells such as T-cells in asthma. Our findings provide evidence that the use of mesenchymal stem cells, their derivatives, and immune cells such as T-cells are an initial milestone to understand how emergent cell-based therapies are effective to face the challenges in the development, progression, and management of asthma, thus improving the quality of life.

show abstract